Maximilien Vermandel

Dr. Maximilien Vermandel

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2018 in Neurosurgery
Verified
Journal Article
Closed access
CDClément Dupont
Clément Dupont
MVMaximilien Vermandel
Maximilien Vermandel
HLHenri-Arthur Leroy
Henri-Arthur Leroy
MQMathilde Quidet
Mathilde Quidet
FLFabienne Lecomte
Fabienne Lecomte
NRNicolas Reyns
Nicolas Reyns
BACKGROUND: Glioblastoma (GBM) is characterized by marked proliferation, major infiltration, and poor prognosis. Despite current treatments, including surgery, radiation oncology, and chemotherapy, the overall median survival is 15 mo and the progression-free survival is 7 to 8 mo. Because of systematic relapse of the tumor, the improvement of local control remains an issue. In this context, photodynamic therapy (PDT) may offer a new treatment modality for GBM. OBJECTIVE: To assess the feasibility of intraoperative PDT early after surgical resection of GBM without unacceptable and unexpected toxicities. METHODS: The INDYGO clinical trial (INtraoperative photoDYnamic Therapy for GliOblastomas) treatment will be carried out in addition to the current standard of care (SOC) of glioblastoma: maximum resection surgery followed by concomitant radio-chemotherapy and adjuvant chemotherapy. PDT treatment will be delivered during surgery early, after the fluorescence-guided resection. Immunological responses and biomarkers will also be investigated during the follow-up. A total of 10 patients will be recruited during this study. EXPECTED OUTCOMES: Clinical follow-up after the SOC with PDT is expected to be similar (no significant difference) to the SOC alone. DISCUSSION: This INDYGO trial assesses the feasibility of intraoperative 5-aminolevulinic acid PDT, a novel seamless approach to treat GBM. The technology is easily embeddable within the reference treatment at a low-incremental cost. The safety of this new treatment modality is a preliminary requirement before a multicenter randomized clinical trial can be further conducted to assess local control improvement by treating infiltrating and nonresected GBM cells.

1 September 2014 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MTMarie-Charlotte Tetard
Marie-Charlotte Tetard
MVMaximilien Vermandel
Maximilien Vermandel
Serge MordonSerge Mordon
Serge Mordon
JLJean-Paul Lejeune
Jean-Paul Lejeune
NRNicolas Reyns
Nicolas Reyns

1 March 2016 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MTMarie-Charlotte Tetard
Marie-Charlotte Tetard
MVMaximilien Vermandel
Maximilien Vermandel
HLHenri-Arthur Leroy
Henri-Arthur Leroy
BLBertrand Leroux
Bertrand Leroux
CMClaude-Alain Maurage
Claude-Alain Maurage
NRNicolas Reyns
Nicolas Reyns

6 May 2015 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
HLHenri‐Arthur Leroy
Henri‐Arthur Leroy
MVMaximilien Vermandel
Maximilien Vermandel
JLJean‐Paul Lejeune
Jean‐Paul Lejeune
Serge MordonSerge Mordon
Serge Mordon
NRNicolas Reyns
Nicolas Reyns

14 November 2015 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
ASA. Schaefer
A. Schaefer
MVMaximilien Vermandel
Maximilien Vermandel
CBC. Baillet
C. Baillet
AVAnne-Sophie VIGNION-DEWALLE
Anne-Sophie VIGNION-DEWALLE
RMR. Modzelewski
R. Modzelewski
UNU. Nestle
U. Nestle

25 September 2017 in Future Oncology
Verified
Journal Article
Closed access
CDClément Dupont
Clément Dupont
Serge MordonSerge Mordon
Serge Mordon
PDPascal Deleporte
Pascal Deleporte
NRNicolas Reyns
Nicolas Reyns
MVMaximilien Vermandel
Maximilien Vermandel
Aim: Photodynamic therapy (PDT) appears to be a valuable new treatment modality for cancer therapy. Studies have reported successful application of PDT for glioblastoma. Here, we introduce a new device dedicated to intraoperative PDT delivered early after fluoro-guided resection combined with a transfer function that determines the treatment time based on the size of the surgical resection cavity. Materials & methods: First, we describe the device, which is composed of a trocar, a balloon filled with a diffusing solution, and a fiber guide in which a cylindrical light diffuser is inserted. Ex vivo experiments were performed to measure the fluence rate inside biological tissues. A calibration factor was defined to convert power measurements into fluence rate values. Calf brains were used to simulate light propagation in human brain tissue, and the photosensitizer administration effect on optical properties was discussed. The temperature elevation during illumination was evaluated. Results: Light power was ...